Developing strategies in the immunotherapy of leukemias

Cancer Control

Volumn 20, Issue 1, 2013, Pages 49-59

  Brayer, Jason B ^a   Pinilla Ibarz, Javier ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A11 PEPTIDE; A2.1 PEPTIDE; A3 PEPTIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; B8 PEPTIDE; CD137 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD33 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; IMMUNOLOGICAL ADJUVANT; IPILIMUMAB; KEYHOLE LIMPET HEMOCYANIN; MYELOBLASTIN; PEPTIDE VACCINE; PR3 PEPTIDE; PROGRAMMED DEATH 1 RECEPTOR; RHAMM R3 PEPTIDE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; WT1 PEPTIDE; ZOLEDRONIC ACID;

ACTIVE IMMUNIZATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL EXPANSION; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; LEUKEMIA; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; REVIEW; STRATEGIC PLANNING; SURVIVAL RATE;

EID: 84871578939     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481302000108     Document Type: Review

References (114)

1. Leukemia and Lymphoma Society. Facts 2012. http://www.lls.org/#/resourcecenter/freeeducationmaterials/generalcancer/. Accessed July 24, 2012.
2. Coley WB. Contribution to the knowledge of sarcoma. Ann Surg. 1891; 14(3):199-220.
3. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphobastic leukemia. Cancer. 2006;106(7):1569-1580.
4. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349-1355.
5. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
6. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118(19):5126-5129.
7. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111(3):1094-1100.
8. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
9. Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007;109(10):2077-2082.
10. Coiffier B, Thieblemont C, Van Den Nest E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de lAdulte. Blood. 2010;116(12): 2040-2045.
11. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581-1588.
12. Zhou J, Bashey A, Zhong R, et al. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant. 2011;17(5):682-692.
13. Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011;34(5):409-418.
14. Goverman J, Gomez SM, Segesman KD, et al. Chimeric immuno- globulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell. 1990;60(6):929-939.
15. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immuno- globulin or T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720-724.
16. Pizzitola I, Agostoni V, Cribioli E, et al. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. J Immunother. 2011;34(16):469-479.
17. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9(3):279-286.
18. Jensen MC, Cooper LJ, Wu AM, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy. 2003;5(2):131-138.
19. Wang J, Press OW, Lindgren CG, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8 cytotoxic T lymphocytes. Mol Ther. 2004;9(14):577-586.
20. James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028-7038.
21. Hudecek M, Schmitt TM, Baskar S, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1- specific chimeric antigen receptor. Blood. 2010;116(22):4532-4541.
22. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620-2630.
23. Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392-6402.
24. Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215-223.
25. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18 pt 1):5426-5435.
26. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66(22):10995-11004.
27. Yu K, Hu Y, Tan Y, et al. Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma. 2008;49(7):1368-1373.
28. Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007;18(8):712-725.
29. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676-684.
30. Tammana S, Huang X, Wong M, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B- cell malignancies. Hum Gene Ther. 2010;21(1):75-86.
31. Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti- lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160-1170.
32. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
33. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
34. Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
35. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
36. Peinert S, Prince HM, Guru PM, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 2010;17(5):678-686.
37. Marin V, Pizzitola I, Agostoni V, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica. 2010;95(12):2144-2152.
38. Giordano Attianese GM, Marin V, Hoyos V, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood. 2011;117(18):4736-4745.
39. Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer. 2011;2:378-382.
40. Terakura S, Yamamoto TN, Gardner RA, et al. Generation of CD19- chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood. 2012;119(1):72-82.
41. Smit WM, Rijnbeek M, van Bergen CA, et al. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 1998;95(17):10152-10157.
42. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis- restricted minor histocompatibility antigens HA-1 or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A. 2003;100(5):2742-2747.
43. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87(9):3587-3592.
44. Berke Z, Andersen MH, Pedersen M, et al. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules. Leukemia. 2000;14(3):419-426.
45. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 1995;85(10):2680-2684.
46. Volpe G, Cignetti A, Panuzzo C, et al. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immuno- therapy approaches. Cancer Res. 2007;67(11):5300-5307.
47. Buzyn A, Ostankovitch M, Zerbib A, et al. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol. 1997;27 (8):2066-2072.
48. Greco G, Fruci D, Accapezzato D, et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia. 1996;10(4):693-699.
49. Nieda M, Nicol A, Kikuchi A, et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood. 1998;91(3):977-983.
50. Osman Y, Takahashi M, Zheng Z, et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia. 1999;13(2):166-174.
51. Wagner WM, Ouyang Q, Pawelec G. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/ bcr can be recognized by both CD4+ and CD8+ T lymphocytes. Cancer Immunol Immunother. 2003;52(2):89-96.
52. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998;101(10):2290-2296.
53. Butt NM, Rojas JM, Wang L, et al. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica. 2005;90(10):1315-1323.
54. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102(8):2892-2900.
55. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95(5):1781-1787.
56. Posthuma EF, Falkenburg JH, Apperley JF, et al. HLA-B8 and HLA- A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood. 1999;93(11):3863-3865.
57. Posthuma EF, Falkenburg JH, Apperley JF, et al. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia. 2000;14(5):859-862.
58. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103(3):1037-1042.
59. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR- ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21(11):2287-2295.
60. Maslak PG, Dao T, Gomez M, et al. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia. 2008;22(8):1613-1616.
61. Jain N, Reuben JM, Kantarjian H, et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009;115(17):3924-3934.
62. Bocchia M, Defina M, Ippoliti M, et al. BCR-ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: interim analysis of a phase 2 multicenter GIMEMA CML Working Party Trial. Blood (ASH Annual Meeting Abstracts). 2009;114:648.
63. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, et al. Synthetic peptide analogs derived from the bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005;90(10):1324-1332.
64. Powles RL, Balchin LA, Fairley GH, Alexander P. Recognition of leukaemia cells as foreign before and after autoimmunization. Br Med J. 1971;1(5747):486-489.
65. Dermime S, Bertazzoli C, Marchesi E, et al. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res. 1996;2(3):593-600.
66. Padua RA, Larghero J, Robin M, et al. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med. 2003;9(11):1413-1417.
67. Cen D, Hu G, Zhou Y, et al. Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RARalpha and hIL-2 genes. Hematology. 2010;15(2):88-95.
68. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95(1):286-293.
69. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101(38):13885-13890.
70. Oka Y, Tsuboi A, Elisseeva OA, et al. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets. 2002;2(1):45-54.
71. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90(7):2529-2534.
72. Molldrem JJ, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88(7):2450-2457.
73. Schmitt M, Li L, Giannopoulos K, et al. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol. 2006;34(12):1709-1719.
74. Chen J, Schmitt M, Bunjes D, et al. The receptor for hyaluronic acid- mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation. Int J Oncol. 2007;30(5):1119-1127.
75. Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111(3):1357-1365.
76. Griffioen M, Kessler JH, Borghi M, et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res. 2006;12(10):3130-3136.
77. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001;193(1):73-88.
78. Scholl S, Salzmann S, Kaufmann AM, et al. Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. Leuk Lymphoma. 2006;47(2):307-312.
79. Gannage M, Abel M, Michallet AS, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol. 2005;174(12):8210-8218.
80. Han JF, Zhao TT, Liu HL, et al. Identification of a new HLA-*0201- restricted cytotoxic T lymphocyte epitope from CML28. Cancer Immunol Immunother. 2006;55(12):1575-1583.
81. Zeis M, Siegel S, Wagner A, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol. 2003;170(11):5391-5397.
82. Kobayashi H, Nagato T, Aoki N, et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother. 2006;55(7): 850-860.
83. Rezvani K, Brenchley JM, Price DA, et al. T-cell responses directed against multiple HLA-*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005;11(24 pt 1):8799-8807.
84. Boublikova L, Kalinova M, Ryan J, et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia. 2006;20(2):254-263.
85. Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21(10):1988-1995.
86. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26):6541-6548.
87. Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010; 116(2):171-179.
88. Kitawaki T, Kadowaki N, Fukunaga K, et al. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br J Haematol. 2011;153(6):796-799.
89. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010;107(31):13824-13829.
90. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90(7):2529-2534.
91. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6(9):1018-1023.
92. Kanodia S, Wieder E, Lu S, et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One. 2010;5(7):e11770.
93. Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2004;104:259.
94. Qazilbash MH, Wieder ED, Thall PF, et al. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival. Blood (ASH Annual Meeting Abstracts). 2007;110:577.
95. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen- specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236-242.
96. Rezvani K, Yong AS, Mielke S, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica. 2011;96(3):432-440.
97. Kirberg J, Bruno L, von Boehmer H. CD4+8- help prevents rapid deletion of CD8+ cells after a transient response to antigen. Eur J Immunol. 1993;23(8):1963-1967.
98. Hunziker L, Klenerman P, Zinkernagel RM, Ehl S. Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells. Eur J Immunol. 2002;32(2):374-382.
99. Deeths MJ, Kedl RM, Mescher MF. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol. 1999;163(1):102-110.
100. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852-856.
101. Kuball J, de Boer K, Wagner E, et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol Immunother. 2011;60(2):161-171.
102. Greiner J, Ringhoffer M, Taniguchi M, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia- associated antigen in acute and chronic myeloid leukemia. Exp Hematol. 2002;30(9):1029-1035.
103. Greiner J, Schmitt A, Giannopoulos K, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica. 2010;95(7):1191-1197.
104. Levitsky HI, Montgomery J, Ahmadzadeh M, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7- 1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol. 1996;156(10):3858-3865.
105. Borrello I, Sotomayor EM, Cooke S, et al. A universal granulocyte- macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther. 1999;10(12):1983-1991.
106. Smith BD, Kasamon YL, Kowalski J, et al. K562/GM-CSF immuno- therapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16(1):338-347.
107. Borrello IM, Levitsky HI, Stock W, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009;114(9):1736-1745.
108. Engels FH, Koski GK, Bedrosian I, et al. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci U S A. 1999;96(18):10332-10337.
109. Smit WM, Rijnbeek M, van Bergen CA, et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol. 1997;53(2):216-223.
110. Heinzinger M, Waller CF, von den Berg A, et al. Generation of dendritic cells from patients with chronic myelogenous leukemia. Ann Hematol. 1999;78(4):181-186.
111. Ossenkoppele GJ, Stam AG, Westers TM, et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia. 2003;17(7):1424-1426.
112. Westermann J, Kopp J, van Lessen A, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol. 2007;137(4):297-306.
113. Hus I, Schmitt M, Tabarkiewicz J, et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia. 2008;22(5):1007-1017.
114. Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009;106(37):15825-15830.